AstraZeneca posts $30.7B sales in six months

AstraZeneca achieved total revenues of $30.7 billion in the first half of 2026, representing a 6% increase compared to the same period last year. The growth is attributed to rising demand for cancer and rare disease treatments. The oncology segment's revenues grew by 15%, reaching $14.12 billion, driven particularly by increased sales of medications like Tagrisso and Imfinzi, especially in the United States. Additionally, revenues from the rare disease sector increased by 11% year-over-year. Overall revenue growth is expected to range between 5% and 9% for the year, supported by increased investment in new research.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل